BioNTech (BNTX) Valuation Check As Shares Rebound Despite Longer Term Return Weakness [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
See our latest analysis for BioNTech. That recent burst of buying interest comes on top of a 12.86% year to date share price return. However, the 1 year total shareholder return of a 4% decline and 3 year total shareholder return of a 23.74% decline show that near term momentum is building from a weaker longer term base. If BioNTech's move has you looking across the sector, this is a good moment to scan other healthcare stocks that might fit your watchlist next. With shares at around $109.12 and a 12.86% year to date return sitting alongside a 23.74% 3 year decline and mixed profitability, is BioNTech a discounted entry point, or is the market already pricing in future growth? Using a fair value of US$139.29 against the last close at US$109.12, the most followed narrative sees meaningful upside already baked into its model assumptions. Robust pipeline expansion in oncology with multiple late stage (Phase II/III) clinical trials for BNT327 and mRNA cancer immunotherapies acr
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]Yahoo! Finance
- Is Regeneron (REGN) Offering Value After Recent Share Price Swings? [Yahoo! Finance]Yahoo! Finance
- AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions [Yahoo! Finance]Yahoo! Finance
- Regeneron CEO: AI is as good as the data it can train on [CNBC]CNBC
- 1 Mooning Stock with Exciting Potential and 2 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 10/28/25 - Beat
REGN
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 4
- 1/7/26 - Form 144
- REGN's page on the SEC website